76 related articles for article (PubMed ID: 8820452)
1. Trial of topotecan as first-line treatment for ovarian cancer announced.
Oncology (Williston Park); 1996 Mar; 10(3):416. PubMed ID: 8820452
[No Abstract] [Full Text] [Related]
2. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
[TBL] [Abstract][Full Text] [Related]
3. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
5. Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
Ozols RF
J Clin Oncol; 1997 Jun; 15(6):2177-80. PubMed ID: 9196128
[No Abstract] [Full Text] [Related]
6. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
8. [Advanced cancer of the ovary. The paclitaxel-cisplatin combination as the first-line standard of treatment].
Pecorelli S
Recenti Prog Med; 1999 Jun; 90(6):338-41. PubMed ID: 10399475
[No Abstract] [Full Text] [Related]
9. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F
Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334
[TBL] [Abstract][Full Text] [Related]
10. Hycamtin achieves promising results in study of patients with leukemia.
Oncology (Williston Park); 1996 Dec; 10(12):1860. PubMed ID: 8985969
[No Abstract] [Full Text] [Related]
11. Clinical studies of topotecan.
Broom C
Ann N Y Acad Sci; 1996 Dec; 803():264-71. PubMed ID: 8993520
[No Abstract] [Full Text] [Related]
12. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
13. Topotecan in the treatment of gynecologic cancer.
Coleman RL; Miller DS
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
[TBL] [Abstract][Full Text] [Related]
14. Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer.
Markman M
Gynecol Oncol; 2007 Jul; 106(1):273-4; author reply 274-5. PubMed ID: 17467780
[No Abstract] [Full Text] [Related]
15. [Choice of first-line chemotherapy for advanced ovarian cancer].
Tiuliandin SA
Vopr Onkol; 1999; 45(4):350-4. PubMed ID: 10532090
[No Abstract] [Full Text] [Related]
16. Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.
Gelderblom H; Sparreboom A; de Jonge MJ; Loos WJ; Wilms E; Mantel MA; Hennis B; Camlett I; Verweij J; van der Burg ME
Br J Cancer; 2001 Oct; 85(8):1124-9. PubMed ID: 11710824
[TBL] [Abstract][Full Text] [Related]
17. Dose intensity in advanced ovarian cancer: have we answered the question?
Fennelly D
Clin Cancer Res; 1995 Jun; 1(6):575-82. PubMed ID: 9816018
[No Abstract] [Full Text] [Related]
18. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
[TBL] [Abstract][Full Text] [Related]
19. Back to the future: multiagent chemotherapy in ovarian cancer revisited.
Cannistra SA
J Clin Oncol; 1999 Mar; 17(3):741-3. PubMed ID: 10071260
[No Abstract] [Full Text] [Related]
20. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]